2026's most popular peptides.

Accelerated healing of tendons, ligaments, muscle, and joint injuries; reduced chronic pain and inflammation; improvements in gut issues (IBS, ulcers, digestive comfort).

Tissue repair across tendon, ligament and gut models. One of the most-studied compounds in the field — but nearly all of it in animals.

10 mg vial + 2 mL water = 5,000 mcg/mL
500 mcg → 0.10 mL  ·  10 units

Accelerated soft-tissue healing (tendons, ligaments, muscles); reduced inflammation and joint pain; improved flexibility and range of motion; faster recovery between workouts.

The research form of thymosin β-4 — wound healing, blood-vessel formation and tissue remodelling.

10 mg vial + 2 mL water = 5,000 mcg/mL
1 mg → 0.20 mL  ·  20 units

One injection covering skin quality, tissue repair, and gut/systemic inflammation at once, instead of running four separate peptides.

A four-peptide blend — GHK-Cu, BPC-157, TB-500 and KPV — combining skin, tissue-repair and anti-inflammatory signalling in a single draw.

80 mg vial + 2 mL water = 40,000 mcg/mL
4 mg → 0.10 mL  ·  10 units

Substantial weight loss (often 10–15%+ of body weight); strong appetite suppression; reduced “food noise”; improved blood sugar and metabolic markers; better energy/mobility after weight loss.

GLP-1 receptor agonist. The most clinically validated peptide here — large randomised trials for glycaemic control and weight.

5 mg vial + 1 mL water = 5,000 mcg/mL
1 mg → 0.20 mL  ·  20 units

Rapid and large-scale weight loss; strong visceral and liver fat reduction; clean energy rather than fatigue; solid appetite control. Often described as stronger than prior GLP-1s.

Investigational triple agonist — GLP-1, GIP and glucagon receptors at once. Phase 2 figures are the largest in the class so far.

10 mg vial + 2 mL water = 5,000 mcg/mL
1 mg → 0.20 mL  ·  20 units

More even daily energy; better exercise recovery and endurance; improved metabolic “feel” (including modest fasting glucose improvements in some); cleaner energy utilization.

A peptide encoded inside mitochondrial DNA, studied as an exercise-mimetic signal tied to energy use and insulin sensitivity.

10 mg vial + 2 mL water = 5,000 mcg/mL
2.5 mg → 0.50 mL  ·  50 units

Higher energy levels; reduced fatigue; sharper mental clarity and focus; improved mood or motivation; general sense of feeling more youthful or recovered (especially injectable/IV forms).

A coenzyme central to cellular energy and DNA repair. Its age-related decline anchors much of modern longevity research.

1000 mg vial + 8 mL water = 125,000 mcg/mL
50 mg → 0.40 mL  ·  40 units

Enhanced focus, working memory, verbal fluency, and mental clarity; neuroprotective-like effects; often described as a clean cognitive boost without heavy stimulation.

Derived from ACTH; developed in Russia and used there in neurology. Studied for focus, memory and neuroprotection via BDNF.

10 mg vial + 2 mL water = 5,000 mcg/mL
500 mcg → 0.10 mL  ·  10 units

Deeper, more restorative sleep (often earliest effect); better workout recovery; gradual improvements in body composition (lean mass gains, fat loss); modest energy or skin quality gains.

A GHRH analogue plus a selective ghrelin-receptor agonist, studied together for a fuller natural GH pulse.

Improved skin firmness, elasticity, and collagen production; reduced fine lines/wrinkles; better wound healing; clearer skin tone; sometimes thicker hair or faster tissue recovery.

Collagen and elastin synthesis, skin firmness, tissue regeneration. The human clinical evidence is TOPICAL, not injected.

Large weight loss (trial averages around 15–20% of body weight at the top doses); strong appetite suppression and reduced “food noise”; better blood sugar and insulin sensitivity; often reported as easier on the stomach than semaglutide for the same result.

Dual GIP and GLP-1 receptor agonist. Approved as Mounjaro (type 2 diabetes) and Zepbound (obesity), with large trial data behind both. A prescription medicine, not a research compound, wherever it is approved.

The two repair peptides in one draw: tendon, ligament and muscle recovery, plus the gut-settling and anti-inflammatory effects people attribute to BPC-157, without running two vials and two injections.

The two most-referenced tissue-repair research peptides, co-supplied in one vial, usually in equal amounts. Each has its own animal literature; the combination itself has essentially none.

Meaningful reductions in visceral abdominal fat; modest gains in lean muscle area/density; smaller waist circumference; improved body composition.

A stabilised GHRH analogue. The only compound on this list FDA-approved for a body-composition indication.

Better sleep quality (deeper, more restorative); more vivid dreams; subtle lift in daytime energy/vitality; occasional reports of improved skin or overall “reset” feeling after short cycles.

A four-amino-acid peptide from Russian gerontology, proposed to activate telomerase.

Skin quality, tissue repair and recovery from a single injection. The “aesthetic” blend: chosen for firmer skin and faster healing together rather than for any one effect on its own.

A three-peptide blend of GHK-Cu, BPC-157 and TB-500 in one vial. KLOW is this plus KPV. No study has tested the combination; whatever evidence exists is borrowed from each component separately.

Fat loss without appetite suppression; a modest metabolic lift; sometimes paired with a GLP-1 in the hope of protecting muscle. Taken orally as a capsule, not injected.

A small-molecule NNMT inhibitor, not a peptide. Studied in cell and mouse models of fat metabolism and fat-cell growth. No human trials at all.

Clear increase in sexual desire and arousal in both men and women; often beginning within 45–90 minutes and lasting several hours; can work independently of visual stimulation for some.

A melanocortin agonist working through the nervous system rather than blood flow. FDA-approved as Vyleesi.

Reduced baseline anxiety and stress reactivity; calm but non-sedating state; improved emotional stability; better performance under pressure; mild mood elevation for some.

Based on the immune fragment tuftsin; developed in Russia as an anxiolytic. Researched for calm and stress resilience.

Similar profile to the CJC-1295 combo but simpler dosing and a smaller reconstitution volume: better sleep, workout recovery, gradual lean-mass and fat-composition change.

A selective ghrelin-receptor agonist and GH secretagogue — the same peptide in the CJC-1295 blend, but also used alone. Raises GH without meaningfully raising cortisol or prolactin.

Rapid tanning with less UV exposure; increased libido and sexual arousal (including spontaneous erections in men); mild appetite suppression alongside skin-darkening effects.

A melanocortin agonist that signals the skin to produce more melanin from less UV exposure.

Improved mitochondrial energy production; reduced fatigue; better exercise tolerance or muscle function (more pronounced with mitochondrial issues); cleaner energy feel. Results more mixed in healthy users.

Also called elamipretide. Targets cardiolipin in the mitochondrial membrane; FDA-approved for a rare genetic disease.

Anti-inflammatory effects; reduced gut discomfort and bloating; calmer inflammatory bowel or mast-cell-related symptoms; general settling of systemic inflammation.

The active C-terminal fragment of α-MSH — anti-inflammatory signalling across gut, skin and immune tissue.

Libido and arousal (most often reported by men); a lift in the body’s own testosterone signalling rather than a replacement for it; occasionally used around fertility.

A fragment of the hormone that sits upstream of GnRH, and so of LH, FSH and testosterone. Human studies exist, mostly in reproductive endocrinology and brain-imaging work on sexual response. Short-acting.

Improved sleep architecture — easier onset, more deep/slow-wave sleep, fewer nighttime awakenings, and feeling more refreshed — without next-day hangover of many sedatives.

Delta sleep-inducing peptide — studied for deep delta-wave sleep activity.

Immune support: fewer or shorter infections; used through illness recovery; sometimes in autoimmune, long-COVID or chronic-fatigue contexts; a general sense of resilience.

Identical to a natural thymic hormone. Approved as Zadaxin in more than 30 countries for hepatitis B and as a vaccine adjuvant, though not in Canada or the US. One of the longer human trial histories on this list.

Weight loss by a different route from the GLP-1s: fullness and slower stomach emptying. Most often run alongside semaglutide (the “CagriSema” pairing) for added effect rather than on its own.

A long-acting amylin analogue. Phase 2 and phase 3 trials, mostly in combination with semaglutide as CagriSema. Investigational: approved nowhere yet.

Fat loss, particularly stubborn abdominal fat, without the appetite effects of a GLP-1; sometimes for joint or cartilage support. Effects, where reported, are described as subtle.

The fat-metabolism fragment of growth hormone (residues 176–191), with the growth-promoting part removed. Went through human obesity trials in the 2000s and failed to show meaningful weight loss. The joint-repair line is preclinical.

Increased muscle fullness and pumps; faster recovery; modest lean-mass gains; better nutrient partitioning; improved training output when timed around workouts and carbohydrates.

A long-acting IGF-1 analogue — the growth factor downstream of growth hormone.

“Exercise in a pill”: endurance, fat oxidation and energy, taken orally. Very new, and the reports are thin.

A small-molecule ERR agonist, not a peptide. Mouse studies only: more endurance and more fat burned with no change in activity. No human data of any kind.

Skin brightening (a major driver of injectable and IV use); liver support and “detox”; recovery from illness or hard training; a general antioxidant reset.

The body’s principal intracellular antioxidant. Decades of clinical use as an IV drug in some countries; the skin-lightening evidence is a handful of small, short trials. Oral absorption is poor, which is why people inject it.

Improved sleep quality; better recovery; increased energy and vitality; gradual lean-mass gains; reductions in body fat (especially visceral) with consistent use.

A GHRH analogue and one of the longest-standing tools in growth-hormone research.